Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Food Research International, 41 , 579585
Supplementary material The Supplementary Material for this article can be found online at: References 1 AhangarN.NaderiM.NorooziA.GhasemiM.ZamaniE.ShakiF
The study found increased risk in both patients with type 2 diabetes and patients using semaglutide for overweight or obesity, but the authors noted that the study was observational and could not prove that semaglutide directly caused NAION
Post-market adverse event databases (FDA MedWatch, EudraVigilance) contain scattered reports of nosebleeds in GLP-1 users, but causality is often unclear
US$ 26.58
US$ 22.63
US$ 23.10
US$ 24.86
US$ 20.06
US$ 21.34
